Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest early breast cancer Stories

2014-04-16 23:03:46

Initial Investment Enables Filing of FDA Class II 510k Now Underway for Pioneer in Early Breast Cancer Detection Reno, NV (PRWEB) April 16, 2014 First Warning Systems, Inc. (FWS), a digital health, wearable body media and large data company for early breast cancer detection, announced it has received $540,000 as the lead in to the company’s Series A funding round of $10 million. The initial investment group is a syndicate of investors primarily from Singapore, as well as a major lead by...

2014-03-18 23:25:20

Popular TV and Blog Healthcare Expert Joins Pioneer in Early Breast Cancer Detection Reno, Nev. (PRWEB) March 18, 2014 First Warning Systems, Inc. (FWS), a digital health, wearable body media and large data company for early breast cancer detection, announced it has appointed Barb Dehn, RN, MS, NP to the company’s Clinical Advisory Board. Known as “Nurse Barb” to legions of her television and blog followers, Dehn is the host of Nurse Barb’s Daily Dose which is broadcast throughout...

2013-09-30 15:44:36

For the first time, researchers have estimated the daily dose of radiotherapy that could be wasted in compensating for cancer cell growth that occurs overnight and during weekends in patients with early breast cancer. In research to be presented to the 2013 European Cancer Congress (ECC2013) today (Monday), Professor John Yarnold will say that, until now, there has been contradictory evidence as to whether gaps between radiotherapy treatments, for instance overnight or at weekends, makes...

2013-01-30 12:26:35

WORCESTER, Mass. and TORONTO, Jan. 30, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today provided an overview on the early breast cancer competitive status of the lead cancer immunotherapy product, AE37, under development at its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). A detailed update on development plans will be provided during the previously announced conference call scheduled for Thursday, January 31, 2013....

2012-11-28 08:30:05

REDWOOD CITY, Calif., Nov. 28, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from six Oncotype® DX breast cancer test studies at the 34(th) Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), taking place December 6-8, 2012 at the Henry B. Gonzalez Convention Center. Presentations include results from evaluations of the Oncotype DX breast cancer test's clinical utility and health economic value in...

2012-03-22 10:58:11

Detecting the presence of circulating tumor cells (CTCs) in the blood of women with early breast cancer after surgery but before the start of chemotherapy can provide useful information about their chances of surviving the disease. CTCs are cancer cells which are detectable in patients with a solid tumor and their value in the prognosis of metastatic breast cancer has been known for a few years. Until now, however, there has been little information about their role in early disease....

2011-09-26 12:23:38

Results from the longest-running trial comparing tamoxifen with the aromatase inhibitor letrozole show unequivocally that letrozole has withstood the test of time and continues to prevent breast cancer recurrences and reduce the risk of death in post-menopausal women with hormone receptor-positive early breast cancer. Professor Richard Gelber told delegates at the 2011 European Multidisciplinary Cancer Congress, in Stockholm today (Monday 26 September) that a 12-year update of results from...

2011-09-26 11:13:34

Findings from major UK trial should change treatment practice, congress told A major UK trial has produced firm evidence that giving radiotherapy between or during chemotherapy cycles to women with early breast cancer significantly reduces the risk of the cancer recurring in the breast or chest wall. The treatment, known as synchronous chemoradiation, has minimal adverse side-effects and no detrimental effect on the patients' quality of life. Findings from the SEquencing of Chemotherapy...

2010-04-12 11:15:00

Research covers nearly 10,000 women A global study of nearly 10,000 women with early breast cancer has found wide variations in how they were treated, despite international consensus on best practice, according to the May issue of the British Journal of Surgery. Researchers from Europe, Japan and America compared 9,779 women with an average age of 64 from 566 study sites in Belgium, France, Germany, Greece, Japan, the Netherlands, the UK/Ireland and the USA. "The primary aim of our five-year...

2009-11-11 02:00:00

Finland, November 11 /PRNewswire/ -- - This is a third party press release. It will be issued by the Finnish Breast Cancer Group on Wednesday 11 November 2009. - FinXX, a Large, Phase III Randomised Study in Women With Early Breast Cancer Shows that Adding Capecitabine (Xeloda(R)) to a Treatment Regimen Containing Standard Agents Allows More Women to Live Cancer-Free for Longer An analysis conducted by the Finnish Breast Cancer Group and published in The Lancet Oncology...